Press
Craif Establishes U.S. Business Office in San Diego – Selected to Join Johnson & Johnson’s JLABS San Diego –
2025.10.15
Tokyo, Japan – October 15 2025 – Craif Inc., a bio-AI startup dedicated to early cancer detection, announced that it has established its first U.S. business office in San Diego, California, located within JLABS San Diego, a global life sciences incubation facility operated by Johnson & Johnson Innovation. This milestone follows the establishment of Craif’s U.S. legal entity in 2022 and the opening of its R&D lab in Irvine, California, in February 2025. With this latest development, Craif is further accelerating its efforts to build a globally scalable model for early cancer detection.
■ Expanding Presence in the United States
Craif’s vision is to help people live out their natural lifespan by enabling early detection and personalized treatment of disease. The company was an early pioneer in the practical application of microRNA (miRNA)—the focus of the 2024 Nobel Prize in Physiology or Medicine—and developed proprietary AI-driven technology to analyze urinary miRNA. Its product, miSignal Scan, enables ultra-early risk detection of hard-to-detect cancers such as pancreatic cancer. The test is now rapidly expanding in Japan, available at over 1,700 medical institutions, 2,000 pharmacies and drugstores, and through e-commerce platforms. Craif initiated clinical trials in Japan to obtain regulatory approval for its software-based diagnostic program targeting pancreatic cancer.Cancer remains a global health challenge. Craif aims to bring its Japan-developed technologies, testing operations, and business model to the United States to help set a new global standard for early cancer detection. The company has already established a U.S. legal entity and an R&D lab, and is actively collaborating with 30 medical institutions across 15 states to collect samples for the early detection of pancreatic cancer, laying the foundation for future insurance reimbursement.Craif has now been selected to join JLABS San Diego, a global life sciences incubator operated by Johnson & Johnson. With this milestone, Craif is accelerating its efforts to build a new social model for early cancer detection and treatment in the U.S. and beyond.
■ U.S. Business Development Overview
- Establishment of U.S. Legal Entity
- Company Name: Craif Inc.
- Incorporation Date: October 4, 2022
- Representative: Ryuichi Onose
- Opening of R&D Lab
- Location: Irvine, California, United States
- Opening Date: February 17, 2025
- Opening of Business Office
- Location: San Diego, California, United States
- Opening Date: October 7, 2025
■ Message from Ryuichi Onose, CEO and Co-Founder of Craif
 | Craif was founded in Japan—a country at the forefront of global demographic challenges such as declining birthrates and aging populations—with the mission to help people live out their natural lifespan by enabling early detection and personalized treatment of disease.Built on Japan’s scientific excellence, we have developed an exceptional and truly innovative early cancer detection technology. Through our product miSignal, we have worked to make Japan the first society in the world where early cancer detection becomes a reality.This challenge continues. Cancer is not a problem unique to Japan—it is a shared global issue. Since our founding, we have been committed to building Craif with a global perspective.Our goal is not only to deliver technology, but to bring Craif’s innovation model—rooted in its groundbreaking technology and designed to address critical societal challenges—from Japan to the world.By joining JLABS San Diego, we are taking a bold step forward in that mission. |
|---|
■ About JLABS
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
■ About Craif
Craif is a Bio-AI startup founded in 2018, focused on advancing the early detection of disease and the realization of personalized treatment.By integrating advanced AI algorithms with our proprietary biomarker analysis platform—NANO IP® (NANO Intelligence Platform)—we decode a wide range of biological signals such as DNA and microRNAs from body fluids including urine.This technology powers the development of groundbreaking diagnostic tests that make ultra-early cancer detection, early treatment, and faster recovery possible.Through the widespread social implementation of biotechnology and AI, Craif is committed to helping people live out their natural lifespan.
